related_result: ctdnajam-20261010-protocol-ccga1-validation-sens-98spec
Related result of CCGA substudy 1 validation set: cancer signal sensitivity at 98% specificity
Per-classifier clinical limits of detection (cTAF at 50% detection, 98% specificity) are shown only in Figure 3 and Figure S2. The text gives one value: the later targeted methylation test, on 559 solid-cancer participants of the second CCGA substudy validation set, had a clinical LOD of 1.3 x 10^-4 cTAF at 98% specificity (3.1 x 10^-4 at its reported 99.3% specificity), described as almost an order of magnitude better than the top classifiers here. That is a different assay on different samples and is not stored as a result.
Descriptive fact transcribed from the pinned source.
Evidence
Source checking verifies the cited claim or transcription. It does not establish independent reproduction.
Evidence table
Inspect claims, sources and review details
Trace each statement to its source and review. A context-only reference supports the record generally; it does not verify an individual field. Source checking does not reproduce an experiment.
One row per statement and cited source. Multiple citations are not independent evaluations. Shared locators are labelled explicitly.
6 evidence rows matching the loaded filters
| Property and statement | Original source and location | Review and provenance |
|---|---|---|
| Claimed field related_result Context-only references | Evaluation of cell-free DNA approaches for multi-cancer early detection Results, clinical LOD from the second CCGA substudy; Figure 3 legend Version: Cancer Cell 40(12):1537-1549.e12, published 2022-12-12; publisher PDF (1-s2.0-S153561082200513X-main.pdf) as deposited by the Francis Crick Institute on figshare, 10.25418/crick.21731870.v1 | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: pdftotext -layout text layer, parsed by extract/extract_ctdna_jamshidi.py |
| Source location Results, clinical LOD from the second CCGA substudy; Figure 3 legend Context-only references | Evaluation of cell-free DNA approaches for multi-cancer early detection Results, clinical LOD from the second CCGA substudy; Figure 3 legend Version: Cancer Cell 40(12):1537-1549.e12, published 2022-12-12; publisher PDF (1-s2.0-S153561082200513X-main.pdf) as deposited by the Francis Crick Institute on figshare, 10.25418/crick.21731870.v1 | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: pdftotext -layout text layer, parsed by extract/extract_ctdna_jamshidi.py |
| Claimed value Per-classifier clinical limits of detection (cTAF at 50% detection, 98% specificity) are shown only in Figure 3 and Figure S2. The text gives one value: the later targeted methylation test, on 559 solid-cancer participants of the second CCGA substudy validation set, had a clinical LOD of 1.3 x 10^-4 cTAF at 98% specificity (3.1 x 10^-4 at its reported 99.3% specificity), described as almost an order of magnitude better than the top classifiers here. That is a different assay on different samples and is not stored as a result. Context-only references | Evaluation of cell-free DNA approaches for multi-cancer early detection Results, clinical LOD from the second CCGA substudy; Figure 3 legend Version: Cancer Cell 40(12):1537-1549.e12, published 2022-12-12; publisher PDF (1-s2.0-S153561082200513X-main.pdf) as deposited by the Francis Crick Institute on figshare, 10.25418/crick.21731870.v1 | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: pdftotext -layout text layer, parsed by extract/extract_ctdna_jamshidi.py |
| Description Descriptive fact transcribed from the pinned source. Context-only references | Evaluation of cell-free DNA approaches for multi-cancer early detection Results, clinical LOD from the second CCGA substudy; Figure 3 legend Version: Cancer Cell 40(12):1537-1549.e12, published 2022-12-12; publisher PDF (1-s2.0-S153561082200513X-main.pdf) as deposited by the Francis Crick Institute on figshare, 10.25418/crick.21731870.v1 | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: pdftotext -layout text layer, parsed by extract/extract_ctdna_jamshidi.py |
| Relationship: subject ctdnajam-20261010-protocol-ccga1-validation-sens-98spec Context-only references | Evaluation of cell-free DNA approaches for multi-cancer early detection Results, clinical LOD from the second CCGA substudy; Figure 3 legend Version: Cancer Cell 40(12):1537-1549.e12, published 2022-12-12; publisher PDF (1-s2.0-S153561082200513X-main.pdf) as deposited by the Francis Crick Institute on figshare, 10.25418/crick.21731870.v1 | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: pdftotext -layout text layer, parsed by extract/extract_ctdna_jamshidi.py |
| Name related_result: ctdnajam-20261010-protocol-ccga1-validation-sens-98spec Context-only references | Evaluation of cell-free DNA approaches for multi-cancer early detection Results, clinical LOD from the second CCGA substudy; Figure 3 legend Version: Cancer Cell 40(12):1537-1549.e12, published 2022-12-12; publisher PDF (1-s2.0-S153561082200513X-main.pdf) as deposited by the Francis Crick Institute on figshare, 10.25418/crick.21731870.v1 | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: pdftotext -layout text layer, parsed by extract/extract_ctdna_jamshidi.py |
Sources and history
Release 2026-10-10-457d7eaef7d6 · Record review: source checked
1 source record and release history
- Evaluation of cell-free DNA approaches for multi-cancer early detection · Original source · Cancer Cell 40(12):1537-1549.e12, published 2022-12-12; publisher PDF (1-s2.0-S153561082200513X-main.pdf) as deposited by the Francis Crick Institute on figshare, 10.25418/crick.21731870.v1
Technical metadata and extraction receipts
Stable ID: ctdnajam-20261010-claim-targeted-methylation-lod
- field
- related_result
- value
- Per-classifier clinical limits of detection (cTAF at 50% detection, 98% specificity) are shown only in Figure 3 and Figure S2. The text gives one value: the later targeted methylation test, on 559 solid-cancer participants of the second CCGA substudy validation set, had a clinical LOD of 1.3 x 10^-4 cTAF at 98% specificity (3.1 x 10^-4 at its reported 99.3% specificity), described as almost an order of magnitude better than the top classifiers here. That is a different assay on different samples and is not stored as a result.
- source locator
- Results, clinical LOD from the second CCGA substudy; Figure 3 legend
- review
- method: source-hash-verification; ai-assisted-source-review; method note: Compared the claim with the cited text of the re-downloaded PDF.; reviewer: claude; reviewer note: Separate Claude review agent, independent of the extractor; no human review claimed; date: 2026-10-10; artifact sha256: 5159294dd203d511dd437837a34555b276e14e0edf615bcb58bae5d9a1246d9a; retrieval url: https://ndownloader.figshare.com/files/38559380; note: Text matches the source. Descriptive claim; no value or execution.